Last $2.25 USD
Change Today -0.06 / -2.60%
Volume 4.2M
GERN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

geron corp (GERN) Snapshot

Open
$2.31
Previous Close
$2.31
Day High
$2.34
Day Low
$2.19
52 Week High
11/7/13 - $7.36
52 Week Low
03/12/14 - $1.31
Market Cap
353.0M
Average Volume 10 Days
2.0M
EPS TTM
$-0.25
Shares Outstanding
156.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GERON CORP (GERN)

geron corp (GERN) Related Businessweek News

No Related Businessweek News Found

geron corp (GERN) Details

Geron Corporation, a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

46 Employees
Last Reported Date: 03/17/14
Founded in 1990

geron corp (GERN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $569.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Executive Vice President of Development and T...
Total Annual Compensation: $367.4K
Executive Vice President of Legal Affairs & H...
Total Annual Compensation: $302.2K
Executive Vice President of Business Developm...
Total Annual Compensation: $341.6K
Compensation as of Fiscal Year 2013.

geron corp (GERN) Key Developments

Geron Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Geron Corporation reported earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss of $8.7 million, or $0.06 per share, compared to $8.9 million, or $0.07 per share, for the comparable 2013 period. Revenues for the second quarter of 2014 were $341,000 compared to $112,000 for the comparable 2013 period. Interest and other income for the second quarter of 2014 amounted to $99,000 compared to $56,000 for the comparable 2013 period. Net loss for the first six months of 2014 was $17.2 million, or $0.11 per share, compared to $20.8 million, or $0.16 per share, for the comparable 2013 period. Revenues for the first six months of 2014 were $815,000 compared to $877,000 for the comparable 2013 period. Interest and other income for the first six months of 2014 was $182,000 compared to $137,000 for the comparable 2013 period.

Geron Corporation and Mayo Clinic Enter into a Transfer Agreement

On July 31, 2014, Geron Corporation and Mayo Clinic entered into a transfer agreement whereby the Investigational New Drug application for imetelstat under which the investigator-sponsored trial to assess the effect of imetelstat in patients with myelofibrosis has been conducted will be transferred to Geron. In addition, the parties have agreed that Geron will assume responsibility for the conduct of the Myelofibrosis IST as the trial sponsor. In connection with entering into the Transfer Agreement, Mayo Clinic has transferred data from the clinical database for the Myelofibrosis IST to Geron. Subject to completion of the obligations and receipt of the deliverables described in the transfer plan that is part of the Transfer Agreement, Geron and Mayo Clinic agreed that the IND and responsibility for the Myelofibrosis IST as the trial sponsor will be transferred to Geron by September 30, 2014. The Company does not intend to enroll additional patients in the Myelofibrosis IST and plans to continue to conduct the Myelofibrosis IST at Mayo Clinic until the trial is closed. The Transfer Agreement also includes certain indemnifications, including, upon completion of the activities set out in the transfer plan and subject to certain customary exceptions, a release of liability from any and all claims by the company arising from the Transferred Information and the IND.

Geron Corporation to Report Q2, 2014 Results on Aug 11, 2014

Geron Corporation announced that they will report Q2, 2014 results After-Market on Aug 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:US $2.25 USD -0.06

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.37 USD -0.0005
BioTime Inc $3.79 USD +0.24
IntelliCell BioSciences Inc $0.0014 USD 0.0001
Neuralstem Inc $3.32 USD +0.06
ReNeuron Group PLC 3.58 GBp +0.125
View Industry Companies
 

Industry Analysis

GERN

Industry Average

Valuation GERN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 300.3x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 185.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit www.geron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.